Treatment of specific non-small cell lung cancer patients Merck MET inhibitors in Germany was reviewed by the FDA as a priority.

Lung cancer is the most common type of cancer in the world and the leading cause of cancer-related deaths.
1.9 million lung cancer deaths worldwide each year.
NSCLC accounts for about 85% of all lung cancer patients.
changes in the MET signaling path, including changes in the MET exon 14 (METex14) jump and MET amplification, occurred in 3% to 5% of NSCLC cases.
Tepotinib is an oral MET inhibitor designed to suppress cancer-causing MET subject signals caused by a mutation in the MET gene.
it has been awarded a breakthrough therapy by the FDA.
March, it was approved by Japan's Ministry of Health, Labour and Human Services (MHLW) to treat patients with METex14 jumping non-removable, advanced or relapsed NSCLC.
is also the first MET inhibitor to receive regulatory approval worldwide.
application is based on key Phase 2 clinical trials.
results showed that the remission rate and long-lasting anti-tumor activity were consistent between different treatment lines, including those with brain metastasis and those assessed by liquid biopsy (LBx) and tissue biopsy (TBx).
preliminary analysis from the VISION study was published in the New England Journal of Medicine (NEJM) on May 29, 2020 and published in the ASCO20 Virtual Science Program of the American Society of Clinical Oncology (ASCO).
the total patient remission rate (ORR) assessed by the Independent Review Board (IRC) was 46% and the patient's medium remission duration (DOR) was 11.1 months.
resources: s1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Retrieved August 25, 2020, from.